Elotuzumab
- Generic Name
- Elotuzumab
- Brand Names
- Empliciti
- Drug Type
- Biotech
- CAS Number
- 915296-00-3
- Unique Ingredient Identifier
- 1351PE5UGS
- Background
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.
- Indication
Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
- Associated Conditions
- Refractory Multiple Myeloma
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2015-09-04
- Lead Sponsor
- Sundar Jagannath
- Registration Number
- NCT02541643
- Locations
- 🇺🇸
Icahn School.of Medicine at Mount Sinai, New York, New York, United States
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- University of Heidelberg Medical Center
- Target Recruit Count
- 564
- Registration Number
- NCT02495922
- Locations
- 🇩🇪
Schwarzwald-Baar Klinikum, Klinik für Innere Medizin II, Villingen-Schwenningen, Germany
🇩🇪Rems-Murr-Klinikum gGmbH Winnenden, Winnenden, Germany
🇩🇪Studienzentrum Aschaffenburg, Aschaffenburg, Germany
Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Hematopoietic Cell Transplantation RecipientPlasma Cell Myeloma
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 113
- Registration Number
- NCT02420860
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
- Conditions
- Multiple Myeloma
- Interventions
- Procedure: Stem Cell Mobilization
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT02375555
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Expanded Access Treatment Protocol CA204-143
- Conditions
- Multiple Myeloma
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT02368301
Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 300
- Registration Number
- NCT02343042
- Locations
- 🇺🇸
Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
- Conditions
- Smoldering MyelomaSmoldering Multiple Myeloma
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 51
- Registration Number
- NCT02279394
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 44
- Registration Number
- NCT02252263
- Locations
- 🇪🇸
Local Institution, Pamplona, Navarra, Spain
🇺🇸The Ohio State University, Columbus, Ohio, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 84
- Registration Number
- NCT02159365
- Locations
- 🇺🇸
Baptist Health Medical Group Oncology, Miami, Florida, United States
🇺🇸Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States
🇺🇸Comprehensive Blood And Cancer Center, Bakersfield, California, United States
Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Conditions
- Plasma Cell LeukemiaPlasma Cell Myeloma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationOther: Laboratory Biomarker AnalysisBiological: Umbilical Cord Blood-Derived Lymphocyte Therapy
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT01729091
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.